Oncternal Therapeutics Q1 2024 GAAP EPS $(2.83) Beats $(2.88) Estimate, Sales $569.000K Beat $176.667K Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics (NASDAQ:ONCT) reported Q1 2024 earnings with a GAAP EPS of $(2.83), surpassing the $(2.88) estimate, and sales of $569,000, exceeding the $176,667 estimate. This represents a significant improvement over the previous year, with a 27.99% decrease in losses per share and a 180.30% increase in sales.

May 09, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncternal Therapeutics reported a smaller loss per share and significantly higher sales than expected in Q1 2024, indicating strong financial performance.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can drive the stock price up in the short term. The significant outperformance in sales and the reduction in losses compared to the previous year highlight operational improvements and financial health, which are key factors investors look for.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100